Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 14

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 14
---
 our board of directors as follows:

| • |     | Serving on our board of directors requires significant time and attention. Directors are expected to spend the time needed and meet as often as necessary to discharge their responsibilities properly. It is expected that, without specific approval from our board of directors: (i) no director shall serve on more than five public company boards (including our board) or on the board of any company that, in our board’s judgment, materially competes with the Company, (ii) if any officer of the Company is also a director of the Company, such officer may not serve on more than two public company boards (including our board), and (iii) no member of the Audit Committee shall serve on more than three public company audit committees (including the Company’s Audit Committee). Directors should advise the chairperson of the Nominating and Corporate Governance Committee before accepting membership on other boards of directors or other significant commitments involving affiliation with other businesses, non-profit entities or governmental units. |

In addition, the nominating and corporate governance committee considers individual qualifications, including relevant career experience, strength of character, maturity of judgment and familiarity with our business and industry, as well as all other factors it considers appropriate for all board nominations, whether made by shareholders or others. 9

The following skills and experiences were considered by the nominating and corporate governance committee in nominating our continuing non-employeedirectors:

| Current Board Member with Substantial Related Experience |     | Core-competency / Experience                                                                    |     | Representative Relevant Skill Sets                                                                                                                                                                                                                                                       |
| Michelle Griffin                                         |     | Compliance and risk management; Therapeutics / Drug Discovery: commercialization expertise      |     | Director of life sciences companies; audit committee chair experience; CEO/CFO experience; overall extensive operational experience in the biotechnology industry and deep experience in public company financial matters; MBA                                                           |
| Robert Hershberg                                         |     | Therapeutics / Drug Discovery: extensive R&D and commercialization expertise                    |     | CEO positions in the biotechnology industry; deep technical expertise; overall extensive executive leadership experience in the biotechnology industry, including operational experience managing sustained revenue and commercial growth in a strategic manner; PhD/MD                  |
| Peter Neupert                                            |     | Diagnostic and Pharmaceutical Services: commercial expertise; Capital growth; Finance (funding) |     | Director of diagnostic laboratory services provider; venture capital provider experience; overall extensive experience in executive leadership roles in the health services sector and as a member of the board of directors of several organizations in the